InVivo surges 56% on news of impending U.S. trial, search for strategic partnerships

InVivo surges 56% on clinical trial news for spinal scaffold

Massachusetts-based InVivo Therapeutics (OTC:NVIV) saw a major surge on Wall Street on Friday after the market reacted to news that it will soon begin enrolling patients in a U.S. clinical trial of its 1st investigational product, diverting development efforts from its hydrogel drug delivery platform.

The study is taking top priority over other efforts, InVivo said, and the company is searching for strategic partners rather than further developing its hydrogel product on its own. InVivo’s already in talks with "a number of prospective corporate partners," but said it’s too soon to discuss time lines or therapeutic areas.

InVivo plans in the 1st quarter of 2014 to launch a clinical study of its degradable polymer scaffold, evaluating the device in treatment of acute spinal cord injuries. More than 10 clinical sites have already signed confidentiality agreements signaling their interest in participating in the human safety trial and members of an independent data safety monitoring committee have already been selected and have agreed to participate, InVivo reported.

The device maker has already begun pouring resources into its spinal scaffold division, taking engineers and other personnel away from hydrogel product development. By February InVivo expects to have enough scaffold inventory on hand to supply the clinical trial and to be able to better "control the quantity, quality and cost of its scaffold."

"For the scaffold trial, InVivo will submit a filing containing proposed changes to its FDA-approved protocol and supporting documents within the next 10 days," the company reported. "The company believes that approval of the proposed changes would accelerate the progress of its trial by eliminating barriers to enrollment and by expanding the number of sites from at least 3 to as many as 6. For instance, the proposed changes would eliminate a substantial amount of burdensome paperwork and other requirements unnecessary for a safety study."

The FDA has 30 days to respond to InVivo’s new filing, according to regulation.

NVIV shares jumped 55.7% by the end of the day Friday, closing at $1.79, but they’re still far from regaining what they lost. In August NVIV shares sank more than 43% in a single day after the company announced new hurdles in negotiations with the FDA. InVivo announced that, under the terms of its FDA investigational device exemption, each patient enrolled in the upcoming spinal scaffold trial must be followed for 3 months and the company must win agency approval before enrolling the next, meaning it will take InVivo an estimated 21 months to enroll its 5 patients. The delays could push back commercialization for years, analysts warned at the time.

That news had come just a day after InVivo announced the sudden departure of chairman, CEO & CFO Francis Reynolds, who resigned suddenly citing a "medical condition." The company watched its shares drop even further following the sudden resignation of interim CFO Sean Moran, who quit after just 2 weeks in the role. Shares regained a few points after InVivo appointed Gregory Perry as the new CFO, but remained 60% lower than they’d been prior to the C-Suite shuffle.

NVIV shares are up about 3% on the year, but down about 38% on the last 6 months.

RSS From Medical Design & Outsourcing

  • MSC Apex Diamond Python and Smart Midsurface speeds modeling to validation
    MSC Software announced a new release of MSC Apex, the company’s award-winning next generation Computer Aided Engineering (CAE) platform. The MSC Apex Diamond Python release introduces: · The fourth release of MSC Apex Modeler is a CAE Specific direct modeling and meshing solution that streamlines CAD clean-up, simplification and meshing workflow. New in this release is […]
  • Quality Metrics: FDA’s plan for a key set of measurements to help ensure manufacturers are producing quality medications
    Editor’s Note: This article is written by Ashley Boam and Mary Malarkey from the “FDA Voice” blog. Boam is an FDA’s acting Director of the Office of Policy for Pharmaceutical Quality, the Office of Pharmaceutical Quality and the Center for Drug Evaluation and Research. Malarkey is an FDA’s Director if the Office of Compliance and Biologics Quality […]
  • MasterControl’s CEO talks EQMS software and new partnerships
    MasterControl offers a quality and compliance software that helps device companies speed time to market and improve their bottom lines. Under Jon’s leadership, the company has blossomed into a market leader and has a unique corporate culture that fosters growth, excellence and quality. In this podcast, MasterControl’s CEO, Jon Beckstrand, will discuss electronic quality management […]
  • BIT Group launches white label IVD solutions
    BIT Group has launched a product line of customizable IVD white label instruments. During recent years, BIT has invested capital and resources developing customizable, ready-to-use IVD systems to address a growing demand. “The IVD market is challenging for our clients,” said Marius Balger, CEO at BIT. “OEM’s must adhere to a growing number of evolving IVD […]
  • Toshiba expands line-up of ARM Cortex-M-based microcontrollers
    Toshiba announced that it has enhanced its current “TX Family” of ARM core-based microcontrollers and started to develop three series of microcontrollers, “TXZ0 series,” “TXZ3 series” and “TXZ4 series,” as part of the “TXZTM Family.” The TXZTM Family is a new collection of flash microcontrollers that support low-power consumption and high-speed operation for IoT and M2M […]
  • Parker Hannifin consolidates, layoffs ahead
    Parker Hannifin plans to consolidate a number of internal divisions, close 2 facilities and expand its Mexican operations, according to an internally distributed letter from Andy Ross, Parker’s engineered materials group president. The company has confirmed the letter was authentic, but has not disclosed how many employees will be affected by the new plans or […]
  • 3-phase current transducer from PEM delivers all-in-one convenience
    The new RCTrms 3-ph current transducer from Power Electronic Measurements (PEM) delivers a convenient, safe and accurate solution for measuring current in three phases. It features a thin, clip-around, flexible sensor coil and provides accurate true rms measurement with 4-20 mA or 0-5 V output, enabling simple installation with PLC’s, SCADA systems or automation equipment. […]
  • Safety alert: Recall on two IV solutions from Baxter
    Baxter International announced it is voluntarily recalling two lots of intravenous (IV) solutions to the hospital and user level due to the potential presence of particulate matter. The particulate matter in each case was determined to be an insect and was identified as a result of a customer complaint. The matter was identified prior to […]
  • TSO3 begins shipment of STERIZONE VP4 Sterilizers to U.S.
    TSO3, a developer in sterilization technology for medical devices in healthcare settings, announced that the company has received purchase orders for multiple devices from the U.S. The orders are the result of the collaborative relationship between Getinge Infection Control, its sales and service provider, and TSO3. “Finally,” said R.M. Rumble, president and CEO of TSO3. “Our Vision is […]
  • Turkish medical company is seeking reseller and OEM partners in the U.S.
    UZUMCU Medical Equipment, one of Turkey’s first and largest manufacturers of medical devices, is seeking reseller and OEM partners in the U.S. The company has an array of FDA-certified OR tables, surgical lights, surgical suction units, electro devices and other medical equipment. “We want to bring our experience with distributors throughout Europe and the Middle […]
  • QImaging introduces new CCD cameras for microscopy with modern software to streamline image capture
    QImaging, a manufacturer of scientific cameras for life science and OEM applications, introduces a new series of Retiga CCD cameras, accompanied by QImaging’s new acquisition software to deliver high-performance tools for microscopy and imaging to researchers at an affordable price. The new QImaging Retiga R1, Retiga R3 and Retiga R6 cameras offer valuable technical features […]

Leave a Reply